June 9, 2020 / 10:54 PM / a month ago

BRIEF-Opthea's OPT-302 Meets Primary Endpoint In Phase 2A Trial In Diabetic Macular Edema

June 10 (Reuters) - Opthea Ltd:

* REPORTS POSITIVE PHASE 2A TRIAL RESULTS OF OPT-302 IN DIABETIC MACULAR EDEMA

* PRIMARY ENDPOINT OF RESPONSE WITH OPT-302 + EYLEA (AFLIBERCEPT) ACHIEVED

* CO-PRIMARY SAFETY ENDPOINT IN PHASE 2A TRIAL OF OPT-302 IN DIABETIC MACULAR EDEMA MET

* NO OCULAR SERIOUS ADVERSE EVENTS REPORTED AND INCIDENCE OF INTRA-OCULAR INFLAMMATION IN STUDY EYE WAS LOW Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below